KCAS Bio Expands Board of Directors with Appointment of Industry Leaders Dr. Paul Kirchgraber and Mr. Kurt Doyle
KCAS Bio, a leading contract research organization (CRO) specializing in comprehensive bioanalytical and biomarker services, today announced the appointment of Dr. Paul Kirchgraber and Mr. Kurt Doyle to its Board of Directors. This strategic addition underscores KCAS Bio’s ongoing growth and evolution as a global leader in life sciences research and development services.
Headquartered in the Kansas City, Kansas metropolitan area, KCAS Bio operates additional sites in the greater Philadelphia area and Lyon, France, along with a partnership in Melbourne, Australia. The company is backed by Vitruvian Partners, one of the world’s foremost growth-focused investment firms.
Dr. Paul Kirchgraber joins the Board with extensive experience in clinical research and laboratory operations. He previously served as Executive Vice President and CEO of Covance, Labcorp’s Drug Development Division, where he oversaw global teams supporting drug and medical device development across more than 60 countries. With leadership spanning pre-clinical, central, and bioanalytical laboratories, as well as clinical services from Phase I through IV, Dr. Kirchgraber brings a wealth of operational and scientific expertise. His tenure as Chairman of the Association of Clinical Research Organizations further reflects his leadership in advancing industry standards and innovation.
Mr. Kurt Doyle brings more than two decades of experience in commercial strategy and business development within the pharmaceutical and biotechnology industries. Over his 26-year career at IQVIA, he most recently held the role of Senior Vice President – Large Pharma and Specialty Services, where he drove growth through client collaboration, operational excellence, and strategic partnerships. Mr. Doyle’s deep understanding of market dynamics and customer needs will enhance KCAS Bio’s mission to deliver client-centric, high-quality research solutions across the entire drug development lifecycle.
“We are thrilled to welcome Paul and Kurt to our Board,” said John Bucksath, CEO of KCAS Bio. “Their leadership and expertise will be invaluable as we continue expanding our scientific capabilities and delivering innovative solutions to our clients. Their strategic insights align perfectly with our commitment to both scientific and operational excellence.”
Sophie Bower-Straziota, Partner at Vitruvian Partners, added, “KCAS Bio has achieved tremendous growth since our initial investment. We’re delighted to welcome Paul and Kurt to the Board as the company continues to strengthen its ability to serve the world’s largest pharmaceutical and biotech organizations—helping them bring critical therapies to patients faster.”
The appointments of Dr. Kirchgraber and Mr. Doyle reflect KCAS Bio’s steadfast commitment to building a world-class leadership team. With their combined expertise, KCAS Bio is well-positioned to accelerate the delivery of life-changing therapies and reinforce its position as a trusted global CRO partner.
About KCAS Bio – KCAS Bio is a leading global Contract Research Organization providing comprehensive GLP-compliant bioanalytical and biomarker development testing services for the biopharma industry. The company offers a complete range of bioanalytical services from early discovery support through new product registration, providing market leading expertise in biological (large molecule) and synthetic (small molecule) drug candidates. Vitruvian’s investments have positioned KCAS Bio to continue growing operations across all its sites globally; continue the rapid hiring of top scientific talent and focus on outstanding customer service; and accelerate internationalization including through acquisitions. KCAS Bio is headquartered in Olathe, Kansas and has c. 380 employees
About Vitruvian – Vitruvian Partners is a global growth-focused investor with offices across London, Miami, San Francisco, Stockholm, Munich, Madrid, Luxembourg, Mumbai, Singapore, and Shanghai. Vitruvian focuses on dynamic situations characterized by rapid growth and change across asset-light industries. Vitruvian has over $20 billion of active funds which have backed many leaders in their sectors, including Just Eat, Arrive, Skyscanner, Medison, CRF Health, DeepIntent, Global-e, and Darktrace.
source link: https://www.businesswire.com
